Hemostemix (CVE:HEM) Stock Price Up 25% – What’s Next?

Hemostemix Inc. (CVE:HEMGet Free Report) shares rose 25% on Friday . The company traded as high as C$0.08 and last traded at C$0.08. Approximately 101,000 shares traded hands during mid-day trading, an increase of 3% from the average daily volume of 98,140 shares. The stock had previously closed at C$0.06.

Hemostemix Stock Performance

The stock’s 50 day simple moving average is C$0.07 and its two-hundred day simple moving average is C$0.06. The firm has a market capitalization of C$5.23 million, a PE ratio of -3.00 and a beta of 0.15.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Read More

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.